Relief For Pradaxa: Praxbind Gets HTA Green Light
This article was originally published in Scrip
Boehringer Ingelheim's Praxbind (idarucizumab), the antidote to the company's blood thinner Pradaxa (dabigatran), is now reimbursed in England, Wales and Ireland after national health technology appraisal bodies said there was no need to put the drug through a full assessment. The news gives Pradaxa a slight advantage over rival novel anticoagulants, which currently do not yet have antidotes, says Datamonitor Healthcare analyst Jack Allen.
Register for our free email digests: